Trial Search Results

An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides

To evaluate the efficacy and safety of topical application of MCH 0.04% in a propylene glycol ointment (PG)in patients with stage I or IIA MF previously treated with MCH 0.02% in a PG or AP ointment who did not achieve a complete response.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Yaupon Therapeutics

Stanford Investigator(s):


  • Drug: 0.04% Mechlorethamine gel


Phase 2


Inclusion Criteria:

   - Patients must have completed the treatment phase of the Yaupon Therapeutics-sponsored
   Phase II Pivotal study of MCH 0.02% in either the PG or AP formulation and have not
   achieved a complete response.

Exclusion Criteria:

   - Pregnant or nursing females, or males and females of childbearing potential, not using
   an effective means of contraception

Ages Eligible for Study

N/A - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Cancer Clinical Trials Office
Not Recruiting